[go: up one dir, main page]

HN2011001697A - Compuesto amino pirazol - Google Patents

Compuesto amino pirazol

Info

Publication number
HN2011001697A
HN2011001697A HN2011001697A HN2011001697A HN2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A
Authority
HN
Honduras
Prior art keywords
pirazol
amino
compound
meloproliferant
chronic
Prior art date
Application number
HN2011001697A
Other languages
English (en)
Inventor
Paul Burkholder Timothy
Ryan Clayton Joshua
Mia Liandong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011001697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001697A publication Critical patent/HN2011001697A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION PROVEE COMPUESTOS AMINO PIRAZOL UTILES EN EL TRATAMIENTO DE TRASTORNOS MIELOPROLIFERANTES CRONICOS Y VARIOS CANCERES
HN2011001697A 2008-12-16 2011-06-16 Compuesto amino pirazol HN2011001697A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
HN2011001697A true HN2011001697A (es) 2013-11-26

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001697A HN2011001697A (es) 2008-12-16 2011-06-16 Compuesto amino pirazol

Country Status (38)

Country Link
US (2) US20100286139A1 (es)
EP (1) EP2379557B1 (es)
JP (1) JP5509217B2 (es)
KR (1) KR101300458B1 (es)
CN (1) CN102232075B (es)
AR (1) AR074240A1 (es)
AU (1) AU2009330503B2 (es)
BR (1) BRPI0923048A2 (es)
CA (1) CA2744714C (es)
CL (1) CL2011001445A1 (es)
CO (1) CO6331442A2 (es)
CR (1) CR20110341A (es)
CY (1) CY1113637T1 (es)
DK (1) DK2379557T3 (es)
DO (1) DOP2011000190A (es)
EA (1) EA019554B1 (es)
EC (1) ECSP11011132A (es)
ES (1) ES2396617T3 (es)
HN (1) HN2011001697A (es)
HR (1) HRP20120918T1 (es)
IL (1) IL213065A0 (es)
JO (1) JO2833B1 (es)
MA (1) MA32900B1 (es)
MX (1) MX2011006441A (es)
MY (1) MY158691A (es)
NZ (1) NZ592641A (es)
PA (1) PA8851101A1 (es)
PE (1) PE20110549A1 (es)
PL (1) PL2379557T3 (es)
PT (1) PT2379557E (es)
SG (1) SG172202A1 (es)
SI (1) SI2379557T1 (es)
SV (1) SV2011003949A (es)
TN (1) TN2011000292A1 (es)
TW (1) TWI440640B (es)
UA (1) UA104743C2 (es)
WO (1) WO2010074947A1 (es)
ZA (1) ZA201103942B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
JP2014513925A (ja) * 2011-03-07 2014-06-19 フォンダッツィオーネ・テレソン Ｔｆｅｂ変異体およびその使用
US9573960B2 (en) * 2011-06-15 2017-02-21 Life & Brain Gmbh Glioblastoma inhibiting compounds and their use
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
PT3179991T (pt) 2014-08-11 2021-11-26 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
KR102611856B1 (ko) * 2016-11-17 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
EP1465889B1 (en) 2001-12-21 2017-03-22 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
EP1899329B1 (en) * 2005-07-01 2011-10-05 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
AR055206A1 (es) * 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
CN101679412A (zh) 2007-05-23 2010-03-24 药典有限责任公司 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
ECSP11011132A (es) 2011-07-29
EA201170831A1 (ru) 2011-12-30
CY1113637T1 (el) 2016-06-22
JP5509217B2 (ja) 2014-06-04
IL213065A0 (en) 2011-07-31
HK1160109A1 (en) 2012-08-10
AU2009330503A1 (en) 2010-07-01
EP2379557B1 (en) 2012-10-31
ES2396617T3 (es) 2013-02-22
EP2379557A1 (en) 2011-10-26
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
US7897600B2 (en) 2011-03-01
WO2010074947A1 (en) 2010-07-01
TWI440640B (zh) 2014-06-11
CO6331442A2 (es) 2011-10-20
TN2011000292A1 (en) 2012-12-17
MX2011006441A (es) 2011-07-19
PE20110549A1 (es) 2011-08-04
KR101300458B1 (ko) 2013-08-30
AR074240A1 (es) 2011-01-05
CR20110341A (es) 2011-07-13
US20100152181A1 (en) 2010-06-17
NZ592641A (en) 2013-01-25
CA2744714A1 (en) 2010-07-01
CN102232075A (zh) 2011-11-02
SG172202A1 (en) 2011-07-28
DK2379557T3 (da) 2012-12-17
JO2833B1 (en) 2014-09-15
DOP2011000190A (es) 2011-07-31
PT2379557E (pt) 2013-01-14
TW201024301A (en) 2010-07-01
PL2379557T3 (pl) 2013-03-29
CL2011001445A1 (es) 2011-11-11
AU2009330503B2 (en) 2012-06-07
UA104743C2 (ru) 2014-03-11
KR20110084993A (ko) 2011-07-26
MY158691A (en) 2016-10-31
CA2744714C (en) 2013-06-25
EA019554B1 (ru) 2014-04-30
ZA201103942B (en) 2012-08-29
SI2379557T1 (sl) 2013-02-28
US20100286139A1 (en) 2010-11-11
CN102232075B (zh) 2013-12-11
HRP20120918T1 (hr) 2012-12-31
JP2012512158A (ja) 2012-05-31
BRPI0923048A2 (pt) 2018-09-25
PA8851101A1 (es) 2010-07-27

Similar Documents

Publication Publication Date Title
HN2011001697A (es) Compuesto amino pirazol
CY2023002I1 (el) Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
ECSP11011441A (es) Compuestos vinil indazolilo
LT2478907T (lt) Kompozicijos vėžiui gydyti
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201170832A1 (ru) Пуриновые соединения
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
EP1996612A4 (en) COMPOSITIONS FOR THE TREATMENT OF CANCER
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
IL243376A0 (en) Antagonist antibody against epha2 for the treatment of cancer
UY31432A1 (es) Compuestos de diarilhidantoina
MA32938B1 (fr) Composes organiques
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
EP2272817A4 (en) PAI-1 INHIBITORS
GT201100181A (es) "inhibidores de proteina cinasa"
HUE043326T2 (hu) Akut limfoblasztos leukémia kezelése
BRPI0821779A2 (pt) tratamento terapêutico de câncer
NL2000439A1 (nl) Therapeutische toepassingen van inhibitoren van RTP801.
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
PL1937244T3 (pl) Leczenie nowotworu specyficznymi agonistami rxr
MX2011007763A (es) Metodos y composiciones para tratamiento de cancer de pulmon.
EP2010216A4 (en) MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
DK2219683T3 (da) Målrettet radioterapi
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów